BRNS BARINTHUS BIO
BARINTHUS BIO (BRNS) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.27 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +33.2% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About BARINTHUS BIO
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases. The company's product pipeline includes VTP-300, VTP-200, VTP-1000, VTP-850 and VTP-1100. Barinthus Biotherapeutics plc, formerly known as Vaccitech plc, is based in OXFORD, United Kingdom.
Sector
Healthcare
Industry
Biotechnology